Firearm injury-related emergency department visit rates increased from 2018 to 2020, then decreased through 2023.
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of various chronic inflammatory diseases.